Centessa Pharmaceuticals plc (CNTA) filed an 8-K on November 5, 2025, primarily to report financial results for the quarter ended September 30, 2025, and provide strategic pipeline updates. The company is an Emerging Growth Company.
Financially, Centessa reported a cash, equivalents, and investments position of $349.0 million as of September 30, 2025, which provides an expected cash runway into mid-2027. The net loss for the quarter was $54.9 million, reflecting increased Research and Development spending ($41.6 million).
The strategic focus remains on advancing the OX2R agonist franchise
...